Should atopic dermatitis patients starting JAK inhibitors take prophylactic acyclovir?

References

• Furumoto Y, Gadina M. The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders. BioDrugs. 2013;27(5):431–438.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78–862.
   PubMed Web of Science ®Google Scholar
• Kubo S, Nakayamada S, Sakata K, et al. Janus kinase inhibitor baricitinib modulates human innate and adaptive immune System. Front Immunol. 2018;9:1510.
   PubMed Web of Science ®Google Scholar
• O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity. 2008;28(4):477–487.
   PubMed Web of Science ®Google Scholar
• Febvre-James M, Lecureur V, Augagneur Y, et al. Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages . Int Immunopharmacol. 2018;54:354–365.
   PubMed Web of Science ®Google Scholar
• Liu T, Khanna KM, Carriere BN, et al. Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons. J Virol. 2001;75(22):11178–11184.
   PubMed Web of Science ®Google Scholar
• Kariyawasam HH, James LK, Gane SB. Dupilumab: clinical efficacy of blocking IL-4/IL-13 signalling in chronic rhinosinusitis with nasal polyps. Drug Des Devel Ther. 2020;14:1757–1769.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. Am J Clin Dermatol. 2019;20(3):443–456.
   PubMed Web of Science ®Google Scholar
• Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford)). 2019;58(Suppl 1):i34–i42.
   PubMedGoogle Scholar
• Winthrop KL, Curtis JR, Lindsey S, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017;69(10):1960–1968.
   PubMed Web of Science ®Google Scholar
• Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv Musculoskelet Dis. 2020;12:1759720X20936059.
   PubMed Web of Science ®Google Scholar
• Colombel JF. Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and Prevention. Inflamm Bowel Dis. 2018;24(10):2173–2182.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24(10):2258–2265.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843–1847.
   PubMed Web of Science ®Google Scholar
• Valor-Mendez L, Voskens C, Rech J, et al. Herpes simplex infection in a patient with rheumatoid arthritis treated with baricitinib: a case report. Rheumatology (Oxford). Apr 6 2021;60(4):e122–e123.
   PubMed Web of Science ®Google Scholar
• Tong LX, Jackson J, Kerstetter J, et al. Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment. J Am Acad Dermatol. 2014;70(3):e59–e60.
   PubMed Web of Science ®Google Scholar
• He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an Update. Am J Clin Dermatol. 2019;20(2):181–192.
   PubMed Web of Science ®Google Scholar
• Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis. J Dermatolog Treat. 2020;31(1):33–40.
   PubMed Web of Science ®Google Scholar
• Wang V, Boguniewicz J, Boguniewicz M, et al. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):3–12.
   PubMed Web of Science ®Google Scholar
• Rystedt I, Strannegard IL, Strannegard O. Recurrent viral infections in patients with past or present atopic dermatitis. Br J Dermatol. 1986;114(5):575–582.
   PubMed Web of Science ®Google Scholar
• Ong PY, Leung DY. The infectious aspects of atopic dermatitis. Immunol Allergy Clin North Am. 2010;30(3):309–321.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Zoch C, Wetzel S, et al. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol. 2003;49(2):198–205.
   PubMed Web of Science ®Google Scholar
• Liaw FY, Huang CF, Hsueh JT, et al. Eczema herpeticum: a medical emergency. Can Fam Physician. 2012;58(12):1358–1361.
   PubMed Web of Science ®Google Scholar
• Finlow C, Thomas J. Disseminated herpes simplex virus: a case of eczema herpeticum causing viral encephalitis. J R Coll Physicians Edinb. 2018;48(1):36–39.
   PubMed Web of Science ®Google Scholar
• Beck LA, Boguniewicz M, Hata T, et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol. 2009;124(2):260–269, 269 e1-7.
   PubMed Web of Science ®Google Scholar
• Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35(2):476–485.
   PubMed Web of Science ®Google Scholar
• King B, Maari C, Lain E, et al. Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials. Am J Clin Dermatol. 2021;22(3):395–405.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Harigai M, Genovese MC, et al. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis. 2020;79(10):1290–1297.
   PubMed Web of Science ®Google Scholar
• Harigai M, Takeuchi T, Smolen JS, et al. Safety profile of baricitinib in japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of phases 2 and 3 trials. Mod Rheumatol. 2020;30(1):36–43.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-Severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863–873.
   PubMed Web of Science ®Google Scholar
• Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–2181.
   PubMed Web of Science ®Google Scholar
• K Reich JL, Costanzo A. Safety of baricitinib in patients with atopic dermatitis: results of pooled data from two phase 3 monotherapy randomized, double-blind, placebo-controlled 16-week trials (BREEZE-AD1 and BREEZE-AD2). presented at: American Academy of Dermatology (AAD) 2020 - 78th Annual Meeting; 2020.
   Google Scholar
• Michal Adamczyk BW. Atopic Dermatitis during Treatment with Selective JAK1 Inhibitor: a case report. Atopic Dermatitis and Pruritus: Interesting Cases. 2021.
   Google Scholar
• Leung DY. Why is eczema herpeticum unexpectedly rare? Antiviral Res. 2013;98(2):153–157.
   PubMed Web of Science ®Google Scholar
• Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748–753.
   PubMed Web of Science ®Google Scholar
• Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs. 1996;52(5):754–772.
   PubMed Web of Science ®Google Scholar
• Gnann JW, Jr., Barton NH, Whitley RJ. Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications. Pharmacotherapy. 1983;3(5):275–283.
   PubMed Web of Science ®Google Scholar
• Xiao A, Tsuchiya A. Eczema herpeticum. StatPearls. 2021.
   Google Scholar
• Gold D, Corey L. Acyclovir prophylaxis for herpes simplex virus infection. Antimicrob Agents Chemother. 1987;31(3):361–367.
   PubMed Web of Science ®Google Scholar
• Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis. 2002;186(s1):S40–S46.
   PubMedGoogle Scholar
• Perazella MA. Crystal-induced acute renal failure. Am J Med. 1999;106(4):459–465.
   PubMed Web of Science ®Google Scholar
• Saral R, Burns WH, Laskin OL, et al. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med. 1981;305(2):63–67.
   PubMed Web of Science ®Google Scholar
• Kawamura K, Hayakawa J, Akahoshi Y, et al. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation. Int J Hematol. 2015;102(2):230–237.
   PubMed Web of Science ®Google Scholar
• Tyring SK, Douglas JM, Jr., Corey L, et al. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The valaciclovir international study group. Arch Dermatol. 1998;134(2):185–191.
   PubMedGoogle Scholar
• Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis. 2004;190(8):1374–1381.
   PubMed Web of Science ®Google Scholar
• Warkentin DI, Epstein JB, Campbell LM, et al. Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients. Ann Pharmacother. 2002;36(10):1525–1531.
   PubMed Web of Science ®Google Scholar
• Fukushima T, Sato T, Nakamura T, et al. Daily 500 mg valacyclovir is effective for prevention of varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib. Anticancer Res. 2012;32(12):5437–5440.
   PubMed Web of Science ®Google Scholar
• Gilbert S, McBurney E. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: a randomized clinical trial of dosing regimens. Dermatol Surg. 2000;26(1):50–54.
   PubMed Web of Science ®Google Scholar
• 500mg Valacyclovir Prescribed Online. GoodRx. 2021.
   Google Scholar
• Guttman-Yassky E, Thaci D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877–884.
   PubMed Web of Science ®Google Scholar